Clinical Data, Inc. (NASDAQ: CLDA) announced operational and financial results for the fourth fiscal quarter and fiscal year ended March 31, 2010, noting the Company’s continued achievement of major clinical and business milestones. Recent Highlights * Company’s new drug application (NDA) for vilazodone for the treatment of major depressive disorder was accepted by the U.S. [...]

Continue reading " Clinical Data, Inc. Reports Fourth Quarter and Fiscal Year 2010 Results "

AVANIR Pharmaceuticals, Inc. (NASDAQ: AVNR) reported unaudited financial results for the three months ended December 31, 2009. For the first quarter of fiscal 2010, AVANIR reported a net loss of $4.8 million, or $0.06 loss per share, compared with a net loss of $5.2 million, or $0.07 loss per share, for the same period in [...]

Continue reading " AVANIR Pharmaceuticals Announces Fiscal 2010 First Quarter Financial Results "

TranSenda International, LLC, announced the deployment of a clinical trial software solution for Harvard Clinical Research Institute (HCRI) that expands the products and services already under contract between the two parties. HCRI was seeking to continue the process of simplifying its existing systems to manage and monitor various spreadsheets, information and documents related to their [...]

Continue reading " TranSenda & Harvard Clinical Research Institute Announce Office-Smart Deployment "

The U.S. Food and Drug Administration has cleared for marketing a new safety engineered short-term peripheral Intra-Venous (IV) Catheter. The product, VantageCath, is designed to significantly reduce exposure to bloodborne pathogens during the placement of the catheter and also provide the clinician with desirable feature sets. Existing safety engineered peripheral IVs have mechanisms to protect [...]

Continue reading " Advantage Medical Devices Receives FDA Clearance for VantageCath "